166 related articles for article (PubMed ID: 16766397)
1. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature.
Taban M; Dupps WJ; Mandell B; Perez VL
Ocul Immunol Inflamm; 2006 Jun; 14(3):145-50. PubMed ID: 16766397
[TBL] [Abstract][Full Text] [Related]
2. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
Braun J; Baraliakos X; Listing J; Sieper J
Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
[TBL] [Abstract][Full Text] [Related]
3. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.
Song IH; Appel H; Haibel H; Loddenkemper C; Braun J; Sieper J; Rudwaleit M
J Rheumatol; 2008 Mar; 35(3):532-6. PubMed ID: 18203308
[TBL] [Abstract][Full Text] [Related]
4. Membranous glomerulonephritis with the use of etanercept in ankylosing spondylitis.
Kaushik P; Rahmani M; Ellison W
Ann Pharmacother; 2011 Dec; 45(12):e62. PubMed ID: 22116994
[TBL] [Abstract][Full Text] [Related]
5. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
6. [Can tumor necrosis factor inhibitors induce sclero-uveitis?].
Le Garrec J; Marcelli C; Mouriaux F
J Fr Ophtalmol; 2009 Sep; 32(7):511.e1-6. PubMed ID: 19535169
[TBL] [Abstract][Full Text] [Related]
7. Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis.
Castro Rocha FA; Silva FS
J Clin Rheumatol; 2010 Mar; 16(2):81-2. PubMed ID: 20130478
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH
Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833
[TBL] [Abstract][Full Text] [Related]
9. [The role of biologic agents in the therapy of ankylosing spondylitis].
Géher P; Nagy MB; Péntek M; Tóth E; Brodszky V; Gulácsi L
Orv Hetil; 2006 Jul; 147(26):1203-13. PubMed ID: 16898082
[TBL] [Abstract][Full Text] [Related]
10. Etanercept therapy-associated acute uveitis: a case report and literature review.
Wang F; Wang NS
Clin Exp Rheumatol; 2009; 27(5):838-9. PubMed ID: 19917170
[TBL] [Abstract][Full Text] [Related]
11. Henoch-Schönlein purpura after etanercept therapy for psoriasis.
Lee A; Kasama R; Evangelisto A; Elfenbein B; Falasca G
J Clin Rheumatol; 2006 Oct; 12(5):249-51. PubMed ID: 17023811
[TBL] [Abstract][Full Text] [Related]
12. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
13. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease.
Gaujoux-Viala C; Giampietro C; Gaujoux T; Ea HK; Prati C; Orcel P; Wendling D; Lioté F
J Rheumatol; 2012 Feb; 39(2):233-9. PubMed ID: 22174213
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
de Vries MK; van der Horst-Bruinsma IE; Nurmohamed MT; Aarden LA; Stapel SO; Peters MJ; van Denderen JC; Dijkmans BA; Wolbink GJ
Ann Rheum Dis; 2009 Apr; 68(4):531-5. PubMed ID: 18375542
[TBL] [Abstract][Full Text] [Related]
15. Onset of lichen planus during treatment with etanercept.
Musumeci ML; Lacarrubba F; Micali G
Am J Clin Dermatol; 2010; 11 Suppl 1():55-6. PubMed ID: 20586513
[TBL] [Abstract][Full Text] [Related]
16. The medical uses and side effects of etanercept with a focus on cutaneous disease.
Scheinfeld N
J Drugs Dermatol; 2004; 3(6):653-9. PubMed ID: 15624748
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration.
Hernandez-Illas M; Tozman E; Fulcher SF; Jundt JW; Davis J; Pflugfelder SC
Eye Contact Lens; 2004 Jan; 30(1):2-5. PubMed ID: 14722460
[TBL] [Abstract][Full Text] [Related]
18. Alopecia areata during etanercept therapy.
Pan Y; Rao NA
Ocul Immunol Inflamm; 2009; 17(2):127-9. PubMed ID: 19412875
[TBL] [Abstract][Full Text] [Related]
19. Optic neuritis with concurrent etanercept and isoniazid therapy.
Noguera-Pons R; Borrás-Blasco J; Romero-Crespo I; Antón-Torres R; Navarro-Ruiz A; González-Ferrandez JA
Ann Pharmacother; 2005 Dec; 39(12):2131-5. PubMed ID: 16264061
[TBL] [Abstract][Full Text] [Related]
20. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
